2,4-Diamino-6-hydroxypyrimidine|56-06-4|(2,4-二氨基-6-羟基嘧啶)-陌孚医药/Medlife

您当前的位置：

2,4-Diamino-6-hydroxypyrimidine (Synonyms: 2,4-二氨基-6-羟基嘧啶)

目录号: PC15143 纯度: ≥98%

CAS No. :56-06-4

商品编号	规格	价格	会员价	是否有货	数量
PC15143-1g	1g	¥490.00	请登录
PC15143-10mM (in 1mL DMSO)	10mM (in 1mL DMSO)	¥490.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	2,4-Diamino-6-hydroxypyrimidine
中文别名	2,4-二氨基-6-羟基嘧啶;2,4-二氨基-6-羟基嘧啶一水合物;2,4-Diamino-6-hydroxypyrimidine 2,4-二氨基-6-羟基嘧啶;2,6-二氨基嘧啶-4-醇;2,6-二氨基-4-嘧啶酮;2,6-氨基-4-嘧啶醇
英文名称	2,4-Diamino-6-hydroxypyrimidine
英文别名	2,6-Diaminopyrimidin-4(1H)-one;2,6-Diamino-4-pyrimidinol;2,4-Diamino-6-hydroxypyrimidine monohydrate;2,6-Diamino-4-Hydroxyprimidine;2,6-Diamino-4-pyrimidinone;2,4-DIAMINO-6(1H)-PYRIMIDINONE;2,4-Diamino-6-hydroxypyrimidine;2,4-Diamino-6-hydroxy;2,4-diaminohypoxanthine;2,6-diamino-4-hydroxy-pyrimidine;2,6-diaminopyrimidin-4-ol;6-Aminoisocytosine;6-hydroxy-2,4-diaminopyrimidine;AURORA KA-376;DAHP;2,4-Diamino-6-pyrimidinol;2,6-Diamino-4-hydroxypyrimidine;2,6-diaminopyrimidin-4(3H)-one;4(1H)-Pyrimidinone, 2,6-diamino-;2,6-Diamino-1H-pyrimidin-4-one;2,6-diamino-3,4-dihydropyrimidin-4-one;2,6-Diamino-4(1H)-pyrimidinone;2,6-Diaminopyrimidin-4-one;2,4-Diamino-6-pyrimidinone;4(3H)-pyrimidinone, 2,6-diamino-;2,4-DAHP
Cas No.	56-06-4
分子式	C₄N₄OH₆
分子量	126.12
包装储存	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

生物活性	2,4-Diamino-6-hydroxypyrimidine is a specific GTP cyclohydrolase I inhibitor (the rate-limiting enzyme in de novo pterin synthesis). 2,4-Diamino-6-hydroxypyrimidine blocks Tetrahydrobiopterin (BH4) synthesis and suppresses NO production.
性状	Solid
IC50 & Target[1][2]	GTP cyclohydrolase I
体外研究(In Vitro)	2,4-Diamino-6-hydroxypyrimidine (DAHP) exhibits a dose-dependent reduction in NO production in both chicken peritoneal macrophages (PECs) and the avian MC29 virus-transformed macrophage cell line, HD11. 2,4-Diamino-6-hydroxypyrimidine (DAHP; 5 mM; 24 hours) treatment significantly reduces both BH4 and VCAM-1 levels during the time course in HUVEC cells. 2,4-Diamino-6-hydroxypyrimidine reduces VCAM-1 and GTPCH protein synthesis at least partially via suppressing the NF-κB level in the nucleus of HUVEC. 2,4-Diamino-6-hydroxypyrimidine (DAHP) is first identified as an inhibitor of the biopterin-dependent growth of the protozoan Crithidia fasciculate. Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	When 2,4-Diamino-6-hydroxypyrimidine (DAHP) is administered for 4 days at the dose of 3 g/kg/day in mice, serotonin decreased in the duodenum and colon to approximately 46% and 40% of the control levels, respectively. 2,4-Diamino-6-hydroxypyrimidine causes a rapid decrease (T_1/2 of less than 12 hr) in the BH4 levels in all tissues examined, except in the brain. The BH4 level returned to within the normal range less than 24 hr after cessation of the administration of 2,4-Diamino-6-hydroxypyrimidine. Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature or refrigerated transportation.
储存方式	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
参考文献	[1]. Sung YJ, et al. 2,4-Diamino-6-hydroxypyrimidine, an inhibitor of GTP cyclohydrolase I, suppresses nitric oxide production by chicken macrophages. Int J Immunopharmacol. 1994 Feb;16(2):101-8. [Information] [2]. Kazuhisa Ikemoto, et al. 2,4-Diamino-6-hydroxypyrimidine (DAHP) suppresses cytokine-induced VCAM-1 expression on the cell surface of human umbilical vein endothelial cells in a BH(4)-independent manner. Biochim Biophys Acta. Jul-Aug 2008;1780(7-8):960-5. [Information] [3]. T Kobayashi, et al. Gastrointestinal serotonin: depletion due to tetrahydrobiopterin deficiency induced by 2,4-diamino-6-hydroxypyrimidine administration. J Pharmacol Exp Ther. 1991 Feb;256(2):773-9. [Information]

溶解度数据

体外研究:

DMSO : 16.67 mg/mL (132.18 mM; Need ultrasonic)

H₂O : 10 mg/mL (79.29 mM; Need ultrasonic)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	7.9290 mL	39.6448 mL	79.2896 mL
5 mM	1.5858 mL	7.9290 mL	15.8579 mL
10 mM	0.7929 mL	3.9645 mL	7.9290 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： PBS
Solubility: 6.5 mg/mL (51.54 mM); Clear solution; Need ultrasonic
2.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1.67 mg/mL (13.24 mM); Clear solution

此方案可获得 ≥ 1.67 mg/mL (13.24 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
3.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.67 mg/mL (13.24 mM); Clear solution

此方案可获得 ≥ 1.67 mg/mL (13.24 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.67 mg/mL (13.24 mM); Clear solution

此方案可获得 ≥ 1.67 mg/mL (13.24 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation